GlassScriptPhysician profile
Robert Jordan Applebaum
NPI 1700175304
$39,405.05
in general payments reported to CMS, 2019-2025
29 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 80% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $495 · 2021: $657 · 2022: $1,909 · 2023: $24K · 2024: $11K · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,313 · Food and Beverage: $4,845 · Consulting Fee: $3,825 · Travel and Lodging: $1,651 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $20,362.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,312.50 |
| Food and Beverage | $4,845.18 |
| Consulting Fee | $3,825.00 |
| Travel and Lodging | $1,650.61 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $25,335.26 | 2019-2023 | Tepezza |
| Amgen INC. | $10,346.16 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $686.29 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $553.29 | 2023-2024 | Purified Cortrophin Gel |
| Coopervision INC. | $305.61 | 2020-2025 | Myday Contact Lens |
| Dompe US, INC. | $227.82 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $168.91 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $152.03 | 2020-2025 | |
| Alcon Vision LLC | $147.35 | 2019-2024 | Rocklatan |
| New World Medical,INC. | $141.97 | 2020 | |
| Galderma Laboratories, L.P. | $125.00 | 2023 | |
| Revance Therapeutics, INC. | $124.83 | 2025 | Daxxify |
| Ethicon US, LLC | $122.12 | 2021 | |
| Sight Sciences, INC. | $115.71 | 2019-2020 | |
| Allergan, INC. | $111.96 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $107.52 | 2022-2023 | |
| Mentor Worldwide LLC | $99.31 | 2019 | |
| Oyster Point Pharma, INC. | $98.44 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $78.24 | 2023-2025 | Botox |
| Bardy Diagnostics, INC. | $75.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $61.26 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $45.26 | 2025 | Xeomin |
| Biotissue Holdings INC. | $43.60 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $27.48 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $26.84 | 2019-2020 | |
| Kerecis Limited | $23.83 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Kala Pharmaceuticals, INC. | $21.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.80 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.